Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

for adult patients with relapsing-remitting multiple sclerosis. While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

“Sanofi can focus even more in bringing innovative solutions to patients suffering from debilitating or life-threatening diseases or viruses such as RSV, COPD, or multiple sclerosis,” Paul ...

Sanofi’s decision to enter this partnership ... concentrating on addressing significant health issues such as RSV, COPD, and multiple sclerosis. This transaction would also enable Opella to ...

Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on November 1 and set a price target ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcareSanofi and CD&R enter exclusive negotiations to transfer a 50% ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

At the same time, Sanofi can focus even more in bringing innovative solutions to patients suffering from debilitating or life-threatening diseases or viruses such as RSV, COPD, or multiple sclerosis.” ...